



Supplementary Figure 1. Kaplan–Meier curves showing no significant effects of certain genetic and immunohistochemical alterations on the overall survival of patients with glioblastomas (1-39). Since the numbers of patients divided into two groups (e.g. FGFR1 Wildtype/FGFR1 Alteration) using different parameters varied, we only enrolled the parameters using which the number of patients in either group was above 3. Parameters used in this section were shown as follows.

(1)	Ki-67 .....	1
(2)	NeuN .....	2
(3)	Syn .....	3
(4)	Oligo2.....	4
(5)	ATRX .....	5
(6)	S-100 .....	6
(7)	GAFP.....	7
(8)	TERT promotor mutation .....	8
(9)	EGFR Amplification .....	9
(10)	CDKN2A/B homozygous deletion.....	10
(11)	Chromosome- 7 gain/10 loss.....	11
(12)	TP53 .....	12
(13)	BRAF .....	13
(14)	CDK6 .....	14
(15)	FGFR1.....	15
(16)	FGFR2.....	16
(17)	FGFR4.....	17
(18)	KIT .....	18
(19)	KRAS .....	19
(20)	MET .....	20
(21)	MYB.....	21
(22)	MYBL1 .....	22
(23)	MYC.....	23
(24)	MYCN .....	24
(25)	NF1.....	25
(26)	NOTCH1 .....	26
(27)	NTRK2.....	27
(28)	NTRK3 .....	28
(29)	PDGFRA .....	29
(30)	PEG3 .....	30
(31)	PIK3CA.....	31
(32)	PPM1D .....	32
(33)	PTEN.....	33
(34)	PTPN11 .....	34
(35)	RB1 .....	35
(36)	TOP3A .....	36
(37)	PIK3R1.....	37
(38)	TSC2 .....	38
(39)	chr17.....	39




(2)




—	60	14	3	2	0	0	0
—	26	12	2	1	1	1	1

(3)




—	16	11	6	3	3	2	2
—	56	38	16	6	0	0	0

(4)




—	7	5	1	1	0	0	0
—	77	50	24	12	4	3	1

(5)




—	6	5	4	3	1	1	1
—	61	40	18	8	4	3	1

(6)



—	3	2	1	1	1	1	1	0	0	0	0	0	0
—	117	75	39	21	11	7	4	3	2	1	1	1	1


(7)



—	3	2	0	0	0	0	0
—	134	42	15	6	3	2	1




(8)




—	38	13	5	2	1	0	0
—	107	34	13	5	2	2	1

(9)



—	23	5	2	1	0	0	0
—	32	11	3	2	1	1	1

(10)



13  
32

5  
8

3  
3


2  
1

1  
0

1  
0


1  
0

(11)




—	3	3	3	2	2	0	0	0	0	0	0	0	0
—	49	30	14	7	5	4	3	3	1	1	1	1	1

(12)




48 18 8 2 0  
67 19 5 1 0

(13)




—	15	3	2	1	0	0	0
—	38	15	6	3	1	1	1

(14)




(15)



—	31	9	5	2	1	1	1
—	22	9	3	2	0	0	0




(16)




—	16	9	4	1	0	0	0
—	37	9	4	3	1	1	1

(17)




—	37	13	8	4	1	1	1
—	16	5	0	0	0	0	0

(18)




—	29	10	5	3	0	0	0
—	24	8	3	1	1	1	1

(19)




—	26	12	6	2	0	0	0
—	27	6	2	2	1	1	1

(20)




—	22	8	4	2	0	0	0
—	31	10	4	2	1	1	1

(21)




—	21	10	6	3	0	0	0
—	32	8	2	1	1	1	1

(22)



—	31	12	6	3	1	1	1
—	22	6	2	1	0	0	0


(23)



—	37	11	6	4	1	1	1
—	16	7	2	0	0	0	0




(24)



—	43	16	7	4	1	1	1
—	10	2	1	0	0	0	0

(25)




—	46	16	7	4	1	1	1
—	7	2	1	0	0	0	0

(26)

Survival probability (%)


All Glioblastomas  
— NOTCH1 Wildtype  
— NOTCH1 Alteration

Log-rank  
 $p = 0.26$




—	35	11	5	2	0	0	0
—	18	7	3	2	1	1	1

(27)




—	26	12	5	4	1	1	1
—	27	6	3	0	0	0	0

(28)



—	32	12	5	4	1	1	1
—	21	6	3	0	0	0	0

(29)



—	26	9	4	2	1	1	1
—	27	9	4	2	0	0	0

(30)

Survival probability (%)

100  
75  
50  
25  
0

0

20

40

Months

60

80

100

120

All Glioblastomas

— PEG3 Wildtype

— PEG3 Alteration

Log-rank  
 $p = 0.71$

— 27  
— 26

10  
8

6  
2


3  
1

0  
1

0  
1

0  
1


(31)



—	20	7	4	2	0	0	0
—	33	11	4	2	1	1	1




(32)




—	37	14	6	3	1	1	1
—	16	4	2	1	0	0	0

(33)




—	14	7	5	2	0	0	0
—	39	11	3	2	1	1	1

(34)




—	39	15	7	4	1	1	1
—	14	3	1	0	0	0	0

(35)




—	21	8	3	1	0	0	0
—	32	10	5	3	1	1	1

(36)




—	27	11	6	3	1	1	1
—	26	7	2	1	0	0	0

(37)



—	49	17	8	4	1	1	1
—	4	1	0	0	0	0	0

(38)



—	50	17	7	4	1	1	1
—	3	1	1	0	0	0	0

(39)

